{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/whooping-cough/prescribing-information/erythromycin/","result":{"pageContext":{"chapter":{"id":"f55a7bd1-232f-5264-b591-1615754d7cd4","slug":"erythromycin","fullItemName":"Erythromycin","depth":2,"htmlHeader":"<!-- begin field 3273e06d-17a3-4a44-9b89-a672a18dc574 --><h2>Erythromycin</h2><!-- end field 3273e06d-17a3-4a44-9b89-a672a18dc574 -->","summary":"","htmlStringContent":"<!-- begin item f49e7df4-987f-4f10-8e1a-dc1fff3812e2 --><!-- end item f49e7df4-987f-4f10-8e1a-dc1fff3812e2 -->","topic":{"id":"35659c4f-d80b-5e8b-8b62-22146482d6da","topicId":"aa36f776-3bec-44aa-ba6f-c147b57f7328","topicName":"Whooping cough","slug":"whooping-cough","lastRevised":"Last revised in January 2021","chapters":[{"id":"57f71ac2-7f00-5c54-b9dc-d2d7d9425e4f","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"43ee7c18-a7d1-5aaf-b7b1-e9f8aec21522","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"c127e190-a190-5b44-9ef6-9f30b6527b35","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"86a8dc5e-4401-57e4-a893-30e9405e7e8d","slug":"changes","fullItemName":"Changes"},{"id":"f0e375ca-3710-5454-996c-600b6987bc09","slug":"update","fullItemName":"Update"}]},{"id":"9165fc1a-9d30-5e58-9bb2-a1b68eab43c6","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"39a4fa70-e2db-566b-9c9e-0be39b8be0ac","slug":"goals","fullItemName":"Goals"},{"id":"7fd8bab1-ed01-583f-925f-50b956b1065b","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"4c330a84-fe34-5261-acf3-bcd6c9b9d2ef","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"dab08320-4d0b-59e9-b25a-28f9cc15908b","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"a088fcbf-b960-56c1-a102-2cb980dc3cb0","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"05a22688-4243-5ec9-814d-874c82306da6","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"32d067f6-839d-500a-9f89-494e3487c3fd","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"76a32750-044c-5bf9-b055-60be74d61d05","slug":"definition","fullItemName":"Definition"},{"id":"ba541f69-d5c7-5bfb-bcef-ec03ceaceee7","slug":"prevalence","fullItemName":"Prevalence"},{"id":"5d07a89e-bdd9-5e79-81eb-87c32d271af2","slug":"prognosis","fullItemName":"Prognosis"},{"id":"054c3198-af7f-5c25-8611-2cc61ad8a848","slug":"complications","fullItemName":"Complications"}]},{"id":"41fa1350-a42e-56da-b04d-aba216545b35","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"6eb9d7f5-32ca-5aaa-b5f3-1ac34aeff0d6","slug":"clinical-features","fullItemName":"Clinical features"},{"id":"02ae0369-3f8d-5a31-b677-d0a1d5d0e6f9","slug":"making-a-clinical-diagnosis","fullItemName":"Making a clinical diagnosis"},{"id":"0a55b0ed-e1e6-5bf2-a57c-ec4bda345338","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"},{"id":"95029ae8-217f-53b1-b552-1b19a63a1460","slug":"notification-confirmation","fullItemName":"Notification and confirmation"}]},{"id":"e9f5a777-75d4-5e44-9222-d0679a35b79f","fullItemName":"Management","slug":"management","subChapters":[{"id":"be786901-8aa4-5cf6-977f-07c667507f85","slug":"management-of-whooping-cough","fullItemName":"Scenario: Management of whooping cough"}]},{"id":"73184dce-2f33-555a-99f5-1f7676165d85","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"c6240279-15ed-57da-bbbc-a009ed1fe10d","slug":"clarithromycin","fullItemName":"Clarithromycin"},{"id":"f55a7bd1-232f-5264-b591-1615754d7cd4","slug":"erythromycin","fullItemName":"Erythromycin"},{"id":"69df3991-1f78-5988-a277-eba775516ffc","slug":"azithromycin","fullItemName":"Azithromycin"},{"id":"83991d80-1c24-5213-80d8-d98f94f7165f","slug":"co-trimoxazole","fullItemName":"Co-trimoxazole"},{"id":"9e55dced-d32c-53b0-9767-ec433fb86549","slug":"paracetamol","fullItemName":"Paracetamol"},{"id":"6a290b31-ff8d-56f2-aa28-4f7fc47c5ff6","slug":"ibuprofen","fullItemName":"Ibuprofen"}]},{"id":"0cb3e998-9c97-56e6-86e8-373f09a16cee","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"06233f93-f6af-5a86-a0d3-f66b18e22f6f","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"933608bb-6634-5ada-9704-c47966180200","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"b65931da-6bf7-5353-a3e6-b7b3f0da241d","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"9e63923e-f250-5bb8-b436-8c4426b094d4","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"8a644bf0-15a8-56ea-a310-b3625c09b8ce","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"4da49df8-81c2-588b-aaf2-014b7ddf9181","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"20d6c374-e4e4-55e9-8247-f63253537476","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"73184dce-2f33-555a-99f5-1f7676165d85","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"b64df98e-1b01-51e7-b840-cd2204073de0","slug":"dose","fullItemName":"Dose","depth":3,"htmlHeader":"<!-- begin field fb215015-6ce2-4238-954a-fd37fd2e1d3b --><h3>Dosing information</h3><!-- end field fb215015-6ce2-4238-954a-fd37fd2e1d3b -->","summary":"","htmlStringContent":"<!-- begin item 89253901-5f71-4711-84f2-003c2204e117 --><!-- begin field d4117f6b-8238-4f06-a1c0-6da1d1edc36a --><ul><li><strong>In adults, </strong>prescribe 500 mg 4 times a day for 7 days.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/whooping-cough/references/\">ABPI, 2016b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/whooping-cough/references/\">BNF 72, 2016</a>]</p><!-- end field d4117f6b-8238-4f06-a1c0-6da1d1edc36a --><!-- end item 89253901-5f71-4711-84f2-003c2204e117 -->","subChapters":[]},{"id":"c88d4402-1eb5-5f04-91ec-c9461e5cc33e","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 1910f872-4733-49cc-9a3a-2831e80f3e3f --><h3>Contraindications and cautions</h3><!-- end field 1910f872-4733-49cc-9a3a-2831e80f3e3f -->","summary":"","htmlStringContent":"<!-- begin item fd4616c2-4816-42f9-9372-e2b42c16c3b4 --><!-- begin field bc5812ed-d20c-4073-bbeb-5af904883b1d --><p><strong>Do not prescribe erythromycin </strong><strong>to people with:</strong></p><ul><li>Porphyria.</li><li>A history of QT interval prolongation or ventricular cardiac arrhythmia.</li><li>Conditions that predispose to QT interval prolongation such as electrolyte disturbances and people taking drugs that prolong the QT interval.</li></ul><p><strong>Prescribe erythromycin with caution </strong><strong>to people with:</strong></p><ul><li>Hepatic impairment (or people concomitantly receiving potentially hepatotoxic drugs) — erythromycin is mainly excreted by the liver.</li><li>Moderate to severe renal impairment:<ul><li>Give a maximum dose for erythromycin of 1.5 g a day in severe renal impairment due to the risk of ototoxicity.</li></ul></li><li>Myasthenia gravis — macrolides may aggravate weakness symptoms.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/whooping-cough/references/\">ABPI, 2016b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/whooping-cough/references/\">BNF 72, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/whooping-cough/references/\">MHRA, 2020</a>]</p><!-- end field bc5812ed-d20c-4073-bbeb-5af904883b1d --><!-- end item fd4616c2-4816-42f9-9372-e2b42c16c3b4 -->","subChapters":[]},{"id":"7058f893-585b-5b8b-b4f7-5735ba6f17b0","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 965ba4c2-8fb8-43b2-a117-d12ec84b30a4 --><h3>Adverse effects</h3><!-- end field 965ba4c2-8fb8-43b2-a117-d12ec84b30a4 -->","summary":"","htmlStringContent":"<!-- begin item ef590324-d95e-4a21-b44f-8ce450f381d7 --><!-- begin field 8d6a3d43-f88f-450b-9567-902fea43643e --><ul><li><strong>Nausea, vomiting, abdominal discomfort, and diarrhoea </strong>are the most common adverse effects of macrolides, and are more common with erythromycin than with clarithromycin.</li><li><strong>Consider pseudomembranous colitis </strong>if a person develops severe diarrhoea during or after treatment with erythromycin.<ul><li>Pseudomembranous colitis is an acute, exudative colitis caused by <em>Clostridium difficile</em>, a Gram-positive toxin-releasing bacillus. It often follows antibiotic treatment. For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/diarrhoea-antibiotic-associated/\">Diarrhoea - antibiotic associated</a>.</li></ul></li><li><strong>Anaphylaxis </strong>is rarely associated with erythromycin.</li><li><strong>Hepatotoxicity (including cholestatic jaundice) and rash </strong>have infrequently been reported following treatment with erythromycin.</li><li><strong>Reversible hearing loss (sometimes with tinnitus) </strong>can occur after large doses of erythromycin (more than 4 g).</li><li><strong>Other adverse effects reported rarely or very rarely include </strong>pancreatitis, QT interval prolongation, arrhythmias, Stevens-Johnson syndrome, and toxic epidermal necrolysis.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/whooping-cough/references/\">ABPI, 2016b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/whooping-cough/references/\">BNF 72, 2016</a>]</p><!-- end field 8d6a3d43-f88f-450b-9567-902fea43643e --><!-- end item ef590324-d95e-4a21-b44f-8ce450f381d7 -->","subChapters":[]},{"id":"da029349-8ce6-5a57-9e23-328d58b12f09","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 208d787f-ce61-4bac-ad41-c60325685d3d --><h3>Drug interactions</h3><!-- end field 208d787f-ce61-4bac-ad41-c60325685d3d -->","summary":"","htmlStringContent":"<!-- begin item dc70fb19-9c75-47fa-b900-dedcf225e658 --><!-- begin field 472d076f-8783-4e09-8eaf-7e4b82503882 --><ul><li><strong>Theophylline — </strong>erythromycin increases plasma concentrations of theophylline, and theophylline may also reduce absorption of oral erythromycin.<ul><li>Check theophylline levels 48 hours after starting erythromycin, and adjust the dose of theophylline accordingly.</li></ul></li><li><strong>Carbamazepine — </strong>erythromycin inhibits the cytochrome P450 enzyme CYP3A4, resulting in reduced carbamazepine metabolism.<ul><li>Advise the person to report symptoms of carbamazepine toxicity (such as dizziness, diplopia, ataxia, or confusion).</li></ul></li><li><strong>Rivaroxaban </strong>— erythromycin may increase levels of rivaroxaban, increasing the risk of bleeding. </li><li><strong>Warfarin — </strong>occasionally and unpredictably, the effects of warfarin may be markedly increased by macrolides.<ul><li>Monitor the international normalized ratio (INR), and adjust the warfarin dose accordingly.</li></ul></li><li><strong>Statins </strong>— there is an increased risk of myopathy (due to cytochrome P450 enzyme CYP3A4 inhibition) if erythromycin is taken with atorvastatin or simvastatin.<ul><li>For simvastatin — do not prescribe erythromycin to a person taking simvastatin, as simvastatin is extensively metabolized by CYP3A4. If treatment with erythromycin cannot be avoided, stop treatment with simvastatin during the course of treatment.</li><li>For atorvastatin — avoid concurrent use with erythromycin, as atorvastatin is moderately metabolized by CYP3A4. If concurrent use cannot be avoided, prescribe the lowest starting dose of atorvastatin (10 mg), and advise the person to report any muscle pain, tenderness, or weakness.</li><li>Other statins — clinically significant drug interactions resulting from cytochrome P450-mediated metabolism are not expected for rosuvastatin and pravastatin as they are not metabolized to a clinically significant extent by the cytochrome P450 system. Fluvastatin is not dependent on CYP3A metabolism; therefore, interaction with erythromycin is unlikely. Nevertheless, advise the person to report any muscle pain, tenderness, or weakness.</li></ul></li><li><strong>Drugs that prolong the QT interval </strong>(such as haloperidol, sotalol, terfenadine, and amisulpride) — all macrolides can prolong the QT interval, and concomitant use of drugs that prolong the QT interval is not recommended.<ul><li>Seek advice from a microbiologist regarding a suitable alternative antibiotic.</li></ul></li><li><strong>Drugs that cause hypokalaemia </strong>(such as diuretics, corticosteroids, short-acting beta<sub>2</sub>-agonists) — hypokalaemia is a risk factor for QT prolongation.<ul><li>Seek advice from a microbiologist regarding a suitable alternative antibiotic.</li></ul></li><li><strong>Calcium channel blockers (CCBs) — </strong>due to an increased risk of hypotension, caution is advised with the concurrent use of macrolides and CCB's metabolised by CYP3A4 (such as verapamil, amlodipine, and diltiazem).</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/whooping-cough/references/\">ABPI, 2016b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/whooping-cough/references/\">BNF 72, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/whooping-cough/references/\">MHRA, 2020</a>]</p><!-- end field 472d076f-8783-4e09-8eaf-7e4b82503882 --><!-- end item dc70fb19-9c75-47fa-b900-dedcf225e658 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}